Clinical Trial

Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 9, 2026 (before its estimated August 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-center, randomized, open-label, two-period, two-sequence crossover bioequivalence study under fed conditions. The primary objective is to evaluate the bioequivalence of a single oral dose of the test formulation compared with the reference formulation in the fed state.
Trial Details
NCT Number NCT07519265
Lead Sponsor Chipscreen Biosciences, Ltd.
Conditions T2DM (Type 2 Diabetes Mellitus)
Enrollment 64 participants
Start Date 2026-07-09
Primary Completion 2026-08-10 (estimated)
Study Completion 2026-08-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-09